Merck KGaA and Fast Forward, LLC Announce Collaboration to Accelerate Development of Treatments for Multiple Sclerosis
Merck and Fast Forward agree to work together to speed research and development on a select group of high potential MS research projects with support of up to $19 million in funding
23-Mar-2009 -
Merck KGaA announced today that its Merck Serono division and Fast Forward, LLC, a wholly-owned subsidiary of the American National Multiple Sclerosis Society, have entered a collaborative partnership to evaluate and fund promising multiple sclerosis (MS) research projects. Proposals will be ...
biotechnology
diagnostics
drug development
+5